SNORD103A: A Potential Drug Target and Biomarker (G692234)

Target Name: SNORD103A

NCBI ID: G692234

SNORD103A

Other Name(s): U103 | small nucleolar RNA, C/D box 103A | Small nucleolar RNA, C/D box 103A

SNORD103A: A Potential Drug Target and Biomarker

SNORD103A is a protein that is expressed in various tissues and cells of the body. Its full name is solute carrier subfamily 10 member 3A, and it is a member of the large gene family known as the subunits of the Na+/K+-ATPase (Na+-ATPase) superfamily. The Na+/K+-ATPase is a transmembrane protein that is involved in the regulation of ion transport and signaling in various organisms, including humans. It is composed of four subunits, including SNORD101, SNORD102, SNORD103, and SNORD104, which are located in the cytoplasm and membrane of the mitochondria.

SNORD103A is a 21-kDa protein that is expressed in various tissues and cells of the body, including the brain, heart, skeletal muscles, and red blood cells. It is involved in the regulation of ion transport and signaling in these tissues and is thought to play a role in the function of the Na+/K+-ATPase.

Drug Target Potential

SNORD103A is a potential drug target due to its involvement in the regulation of ion transport and signaling. Ion transport is a critical process that involves the movement of charged particles, such as ions, across the membrane of the cell. The Na+/K+-ATPase is involved in this process by generating ATP through a catalytic cycle that involves the transfer of a phosphate group from the ATP synthase to the alpha subunit of the Na+/K+-ATPase. This process is thought to play a role in the regulation of ion transport and signaling in various tissues and cells of the body.

SNORD103A is a key protein in the Na+/K+-ATPase signaling pathway, and its regulation of ion transport and signaling may be the target of future drug development. Studies have shown that inhibitors of the Na+/K+-ATPase can be effective in treating a variety of conditions, including hypertension, heart failure, and neurodegenerative diseases. Therefore, SNORD103A is a promising target for drug development.

Biomarker Potential

SNORD103A is also a potential biomarker for various diseases. Its regulation of ion transport and signaling is thought to be involved in the development and progression of various diseases, including neurodegenerative diseases, cardiovascular diseases, and diabetes.

For example, studies have shown that SNORD103A is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroinclusions. The regulation of ion transport and signaling by SNORD103A may be involved in the progression of these conditions.

In addition, SNORD103A has also been shown to be involved in the regulation of cardiovascular disease. Studies have shown that inhibitors of the Na+/K+-ATPase can be effective in treating hypertension, a common cardiovascular disease. In addition, SNORD103A may also be involved in the regulation of blood pressure, as has been shown in animal models of hypertension.

Conclusion

SNORD103A is a protein that is involved in the regulation of ion transport and signaling in various tissues and cells of the body. Its regulation of ion transport and signaling is thought to play a role in the development and progression of various diseases, including neurodegenerative diseases, cardiovascular diseases, and diabetes. Therefore, SNORD103A is a promising target for drug development and a potential biomarker for these conditions. Further studies are needed to fully understand the role of SNORD103A in these processes and to develop effective treatments.

Protein Name: Small Nucleolar RNA, C/D Box 103A

The "SNORD103A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD103A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets